Key result
Pharmacoinvasive strategy reduces 30-day reinfarction and recurrent ischemia vs fibrinolysis alone in STEMI.
Why the study?
To compare the pharmacoinvasive strategy versus fibrinolysis alone in adults with ST-segment elevation myocardial infarction.
Does a pharmacoinvasive strategy (fibrinolysis followed by routine early PCI) reduce hard clinical endpoints such as mortality and reinfarction in adults with ST-segment elevation myocardial infarction compared to fibrinolysis alone?
Meta-Analysis (n=3,053)
Yes
Does a pharmacoinvasive strategy (fibrinolysis followed by routine early PCI) reduce hard clinical endpoints such as mortality and reinfarction in adults with ST-segment elevation myocardial infarction compared to fibrinolysis alone?
A pharmacoinvasive strategy for STEMI reduces reinfarction, recurrent ischemia, and the need for revascularization without increasing major bleeding compared to fibrinolysis alone, supporting its use when timely primary PCI is unavailable.
Answers are grounded in this paper and cite their sources.
Supports pharmacoinvasive strategy in STEMI when timely primary PCI unavailable; strengthens RCT evidence for reduced ischemic events without excess bleeding.
OBJECTIVE: To compare the pharmacoinvasive strategy (PS) versus fibrinolysis alone in adults with ST-segment elevation myocardial infarction. METHODS: We searched PubMed/MEDLINE, Web of Science, Embase, and Cochrane Library from inception until January 17th, 2025. The review protocol was registered in PROSPERO (CRD42022309130). We included randomized controlled trials (RCTs), assessed risk of bias with the Cochrane Risk of Bias 1.0 tool, and calculated pooled relative risks and mean differences. We used GRADE's minimally contextualized approach to determine the certainty of the evidence. RESULTS: We found 7 RCTs (n = 3053). The PS, compared to fibrinolysis alone, may have an important reduction on mortality (3.3% vs 3.9%; -5 per 1000; 95% CI: -16 to +10); and has an important reduction on reinfarction (2.6% vs 4.4%; -19 per 1000; 95% CI: -27 to -6), revascularization (9.0% vs 26.8%; -169 per 1000; 95% CI: -220 to -64), and recurrent ischemia (1.2% vs 5.7%; -46 per 1000; 95% CI: -52 to -27) at 30 days follow up. Similar results were found at longest follow up for the outcomes mentioned. PS probably has an important reduction on mean hospital stay length at longest follow up (-2.47 days; 95% CI: -4.17 to -0.78) and may reduce cardiac failure and cardiogenic shock at 30 days, but the evidence is very uncertain. PS has trivial or no effect on major bleeding (4.6% vs 5.0%; -4 per 1000; 95% CI: -17 to +13) and may have an important reduction on stroke (0.7% vs 1.3%; -6 per 1000: 95 CI: -10 to +2). CONCLUSIONS: The PS has an important reduction on reinfarction, revascularization, and recurrent ischemia; probably has an important reduction on mean hospital stay length; and may have an important reduction of mortality and stroke. Also, PS may reduce cardiac failure and cardiogenic shock, but the evidence is very uncertain. The risk of major bleeding did not increase.
No takes yet. Share an insight, caveat, or question.
Soriano‐Moreno et al. (2025) conducted a meta-analysis in ST-elevation myocardial infarction (STEMI) (n=3,053). Pharmacoinvasive strategy (fibrinolysis plus PCI within 2-24 hours) vs. Fibrinolysis alone was evaluated on Mortality at 30 days (RR 0.87, 95% CI 0.59 to 1.27). In adults with STEMI, a pharmacoinvasive strategy reduced 30-day reinfarction, revascularization, and recurrent ischemia compared to fibrinolysis alone, with no significant difference in 30-day mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: